Strategic Acquisition Leverage the recent acquisition of PROGEN Biotechnik GmbH by Yuhan USA as a sales trigger to offer continuity in product access, cross-sell premium antibodies and AAV tools to a broader, integrated customer base, and position as a partner with scale and global reach.

AAV leadership Capitalize on PROGEN's strong AAV analytical tools, ELISA kits, and viral titer assays by targeting gene therapy developers needing validated capsid quantification and analytical workflows, highlighting compatibility with existing Bio-Techne and Thermo Fisher ecosystems.

Thermo Fisher Tie Target customers and distributors who rely on Thermo Fisher Scientific by offering PROGEN antibodies and AAV tools through non-exclusive distribution channels, presenting complementary solutions to expand end-to-end research capabilities.

Lifecycle Partnerships Position PROGEN as a research-enabled partner throughout the drug development journey by offering integrated support services, custom reagents, and assay development help to academia and pharma, increasing customer lifetime value.

Growth Markets Highlight the expanding gene therapy market and PROGEN’s proven delivery kits and specialized proteins to biotech startups and contract research organizations seeking reliable, scalable tools for R&D and manufacturing support.